C-Rad AB Class B (CRAD.B) AI Stock Analysis

• Market Cap: €1.06B
• Dividend Yield: N/A
• Average Volume (3M): 37.70K
• Price to Earnings (P/E): 18.7
• Beta (1Y): 0.42
• Revenue Growth: 2.53%
• EPS Growth: -44.90%
• Country: SE
• Employees: 99
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Devices
• EPS (TTM): -0.24
• Shares Outstanding: 32,904,050
• 10 Day Avg. Volume: 25,384
• 30 Day Avg. Volume: 37,696
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

C-Rad AB Class B demonstrates strong financial performance with robust growth, profitability, and stability, contributing significantly to its overall score. Technical analysis shows mixed signals, with the stock trading below key moving averages but some potential for reversal indicated by other metrics. The company's valuation appears reasonable with a moderate P/E ratio, though the lack of a dividend may deter income-focused investors. Overall, the company is well-positioned for continued success, though monitoring of market trends and financial metrics is advised.

C-Rad AB Class B Business Overview & Revenue Model

Company Description

C-Rad AB Class B (CRAD.B) is a Swedish company specializing in advanced radiation therapy technologies. The company operates in the healthcare sector, focusing primarily on providing innovative solutions for cancer treatment. C-Rad's core products include surface-guided radiation therapy systems, patient positioning solutions, and related software tools that enhance precision and safety in radiation therapy procedures.

How the Company Makes Money

C-Rad AB generates revenue through the sale of its radiation therapy products and services to hospitals and cancer treatment centers worldwide. The company's key revenue streams include the direct sales of its advanced surface-guided radiation therapy systems and associated software licenses. Additionally, C-Rad offers support and maintenance services, providing ongoing technical support and system upgrades, which contribute to recurring revenue. Significant partnerships with healthcare providers and institutions also play a crucial role in expanding C-Rad's market reach and driving sales growth.

C-Rad AB Class B Financial Statement Overview

Summary

C-Rad AB Class B is performing well across all financial statement verticals. The company shows strong growth, profitability, and stability, with a robust income statement, a solid balance sheet, and healthy cash flows. The financial metrics indicate effective management and potential for continued success in the Medical Equipment & Supplies industry. However, continued monitoring of cash flow fluctuations and maintaining growth momentum will be essential.

Income Statement

C-Rad AB Class B has demonstrated a strong revenue growth trajectory with a 10.45% increase in 2024. The company also maintains healthy profit margins, with a gross profit margin of approximately 68.87% and a net profit margin of 12.04% in 2024. The EBIT and EBITDA margins indicate strong operational efficiency. Overall, the income statement reflects a robust financial performance with consistent growth and profitability.

Balance Sheet

The balance sheet of C-Rad AB Class B is solid, with a low debt-to-equity ratio of 0.03, indicating minimal leverage. The equity ratio stands at 66.42%, reflecting a strong capital structure. The company also boasts a high return on equity of 17.38%, showcasing effective use of shareholder funds. The balance sheet exhibits stability and financial health, minimizing potential risks associated with high leverage.

Cash Flow

C-Rad AB Class B displays a positive trend in cash flow generation, with free cash flow growing significantly compared to previous years. The operating cash flow to net income ratio of 0.53 indicates strong cash generation capabilities. Despite fluctuations in investing and financing activities, the company maintains healthy cash flow positions, supporting its operational and growth needs.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
469.00M	424.62M	301.33M	261.15M	221.63M
	Gross Profit
323.00M	287.21M	205.30M	170.23M	136.89M
	EBIT
70.00M	44.24M	21.76M	35.99M	17.08M
	EBITDA
79.90M	53.10M	27.51M	45.71M	26.15M
	Net Income Common Stockholders
56.50M	35.53M	7.48M	25.10M	14.37M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
150.90M	129.36M	121.90M	122.42M	108.05M
	Total Assets
489.40M	405.54M	339.17M	306.71M	270.52M
	Total Debt
9.00M	1.75M	4.08M	6.37M	7.44M
	Net Debt
-141.90M	-127.60M	-117.82M	-116.05M	-100.61M
	Total Liabilities
164.40M	134.36M	96.63M	75.62M	70.73M
	Stockholders Equity
325.00M	271.18M	242.54M	231.09M	199.79M
Cash Flow		Free Cash Flow
29.90M	16.45M	-1.53M	12.37M	11.66M
	Operating Cash Flow
29.90M	33.38M	9.69M	18.17M	18.45M
	Investing Cash Flow
-6.50M	-16.93M	-11.22M	-5.80M	-6.78M
	Financing Cash Flow
-7.10M	-5.69M	-2.38M	1.04M	68.01M

C-Rad AB Class B Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 30.15
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CRAD.B, the sentiment is Negative. The current price of 30.15 is above the 20-day moving average (MA) of 29.71, above the 50-day MA of 29.92, and below the 200-day MA of 33.33, indicating a neutral trend. The MACD of 0.27 indicates Negative momentum. The RSI at 52.09 is Neutral, neither overbought nor oversold. The STOCH value of 23.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CRAD.B.

C-Rad AB Class B Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	74 Outperform	€1.06B	18.74	10.11%	―	2.53%	-44.90%
MNTC	54 Neutral	€524.16M	―	-12.29%	―	6.11%	-553.72%
Sector *	52 Neutral	$5.15B	3.56	-42.19%	2.83%	14.48%	-0.49%
ACARIX	46 Neutral	€218.07M	―	-102.63%	―	-0.61%	54.19%
SEDANA	46 Neutral	€1.23B	―	-5.61%	―	13.66%	-139.90%
INTEG.B	43 Neutral	€317.03M	―	-12.79%	―	-6.43%	-323.52%

C-Rad AB Class B Corporate Events

C-RAD AB Reports Solid Q1 2025 Amid Market Challenges

C-RAD AB reported a solid first quarter in 2025, with a 5% increase in order intake and a slight revenue growth of 1% despite challenging market conditions. The company’s EBIT was impacted by unrealized currency effects, but the underlying profit remained strong. C-RAD continues to focus on strategic priorities, such as increasing market share, investing in product innovation, and expanding its service business. The company achieved significant growth in the service sector, particularly in EMEA and APAC, and secured important contracts in the US, UK, and other regions. Despite uncertainties in the market due to geopolitical and tariff issues, C-RAD remains committed to its long-term goals of achieving profitable growth and enhancing its product offerings.

C-RAD Sets Ambitious Medium-Term Financial Targets

C-RAD has announced its medium-term financial targets, aiming for an average organic growth of over 10% and an operating margin of 25%. The company plans to return at least 30% of net profit to shareholders. Their strategy includes increasing market share, product innovation, and enhancing service offerings to build a resilient and profitable business, which will be detailed further in their upcoming presentation.